OncLive SOSS

Clinical Advances in Nasopharyngeal Carcinoma - Episode 8

Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma

September 11, 2024

Barbara Burtness, MD, Victoria M. Villaflor, MD, Shravan Kandula, MD

The panel provides clinical insights on nasopharyngeal carcinoma treatment practices and outlines unmet needs in the current therapeutic landscape.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach

EP. 2: Current Guidelines for Managing Nasopharyngeal Carcinoma

EP. 3: Overview of the JUPITER and POLARIS-2 Trials

EP. 4: Value of PD-L1 Biomarker in NPC

EP. 5: Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab

EP. 6: Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors

EP. 7: Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment

EP. 8: Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma

EP. 9: Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects

EP. 10: Clinical Scenario: Locally Recurrent NPC

EP. 11: Clinical Scenario: Metastatic EBV-Positive NPC

Video content above is prompted by the following:

What further research is needed to better understand the long-term benefits and risks of neoadjuvant/adjuvant PD-1 blockade this patient population?

x